Pure Global

Roche Cobas automatic blood coagulation analyzer series - Taiwan Registration 3aa02f36b0229f085f29300d99989cee

Access comprehensive regulatory information for Roche Cobas automatic blood coagulation analyzer series in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 3aa02f36b0229f085f29300d99989cee and manufactured by Roche Diagnostics International Ltd;; ROCHE DIAGNOSTICS GMBH. The authorized representative in Taiwan is ROCHE DIAGNOSTICS LTD..

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
89,000+ Devices
3aa02f36b0229f085f29300d99989cee
Registration Details
Taiwan FDA Registration: 3aa02f36b0229f085f29300d99989cee
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Roche Cobas automatic blood coagulation analyzer series
TW: ็พ…ๆฐๅฏ้œธๆ–ฏๅ…จ่‡ชๅ‹•่ก€ๆถฒๅ‡ๅ›บๅˆ†ๆžๅ„€็ณปๅˆ—
Risk Class 2

Registration Details

3aa02f36b0229f085f29300d99989cee

DHA05603199408

Company Information

Product Details

This product is fully automated, random can be continuously put on the machine, software-controlled system, used for coagulation, color and immunoturbidimetry analysis, used in a variety of coagulation tests, in vitro qualitative and quantitative coagulation determination, the results are used to assist the diagnosis of coagulation abnormalities and the monitoring of anticoagulant therapy. This product is a system for the determination of coagulation analytes using human citric acid plasma.

B Hematology, pathology, and genetics

B.5425 Versatile system for in vitro agglutination studies

Input;; Contract manufacturing

Dates and Status

Dec 28, 2018

Dec 28, 2028